In summary, throughout the last decade one of the most spectacular advantage is reached in HER2/neu-overexpressing MBC. Introduction of bevacizumab being a VEGF-directed focused treatment method continues to be an issue on debate. Some of the novel therapeutics on the breast most cancers armamentarium resulted in prolongation of survival for patien